Compounds · Oral incretins

About the Oral incretins category

Compounds › Oral incretins oral semaglutide orforglipron PIONEER programme

Pinned Wiki

s.leclercTL4 Moderator3 May 2026#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by hana.sato on 8 Jul 2026.

2 Jul 2026 — s.leclerc: Restructured into sections so the outline is navigable.
8 Jul 2026 — hana.sato: Corrected an arithmetic slip in the second example.

Editors: s.leclerc, mira.patel, hana.sato

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

Questions specific to oral incretins, with the units and the context stated.
Reports and datasets, with the collection method stated.
Disagreement about the substance, conducted in public.

What belongs elsewhere

Anything urgent belongs in Safety, immediately, and not here.
Anything about how this site works belongs in Meta.
Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

5 likes 3mo

j.mwangiTL4 Moderator25 May 2026#2

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Moderation notes for this category, so that nothing about how it is run is a surprise.

Topics get moved into and out of here regularly. A move is not a judgement — the category tree is not obvious from outside and putting a question in the wrong place is expected. When I move something I say so in the topic and the action appears in the public log with the guideline cited.

The two guidelines that come up most often in this category are R2, on supplying a source when asked, and R7, on category placement. Neither is used punitively.

9 likes 2mo

buffer_marginTL3Regular11 Jun 2026#3

As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic list shows you what is recent. The tags show you what is settled.

28 likes 2mo

e.mensaTL2 Moderator25 Jun 2026#4

Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note.

0 likes 1mo

r.venkatesanTL3Wiki editor8 Jul 2026#5

The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.

0 likes 20d

Suggested topics

Topic	Participants	Replies	Views	Activity
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+27	31	17k	25d
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on Compounds › Oral incretins PIONEER programme SOUL trial orforglipron Solved Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…	+16	20	18k	2mo
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Compounds › Oral incretins orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+100	104	4.2k	5mo
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…	+48	52	59k	18mo

Related topics — sharing the tags oral semaglutide, orforglipron, PIONEER programme

Topic	Participants	Replies	Views	Activity
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? Compounds › Oral incretins orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…	+23	27	4.8k	22mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Compounds › Oral incretins PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
SNAC and the mechanism of oral peptide absorption — the long version Compounds › Oral incretins oral semaglutide randomised trial orforglipron SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+32	36	6.8k	16mo
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →